BioSpace News Archive

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares,

Clovis Oncology, Inc. announced that it has commenced an underwritten public offering of common stock.

Plummeting revenues and rising expenses during New Jersey’s COVID-19 crisis have had a severe impact on hospitals’ finances, with the statewide hospital operating margin plunging to negative 30 percent, according to a financial impact analysis from the New Jersey Hospital Association.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock.

Bureau Veritas, a world leader in testing, inspection, and certification services announced Cleveland Clinic will serve as their Chief Medical Director for its “Restart your Business with BV” program that includes operation continuity audits, laboratory hygiene testing, safety protocol audits, and more.

Timber Pharmaceuticals, Inc., (NYSE American: TMBR), formerly known as BioPharmX Corporation (“Timber” or the “Company”), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that its merger with Timber Pharmaceuticals LLC

Clovis Oncology, Inc. announced the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions.

Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416,667 shares of its common stock at a price to the public of $60.00 per share.

bluebird bio, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.